CorMedix
CRMD
12 hedge funds and large institutions have $3.78M invested in CorMedix in 2014 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 4 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0.05% more ownership
Funds ownership: 1.85% → 1.9% (+0.05%)
14% less funds holding
Funds holding: 14 → 12 (-2)
26% less capital invested
Capital invested by funds: $5.08M → $3.78M (-$1.3M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$121K |
| 2 |
Millennium Management
New York
|
+$63.9K |
| 3 |
Morgan Stanley
New York
|
+$19.5K |
| 4 |
GLRA
Gerald L. Ray & Associates
Dallas,
Texas
|
+$8.1K |
| 5 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
+$6.64K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIM
Spark Investment Management
New York
|
-$146K |
| 2 |
Goldman Sachs
New York
|
-$11.8K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.53K |
| 5 |
HCC
Hirtle Callaghan & Co
West Conshohocken,
Pennsylvania
|
-$1K |
CRMD Hedge Fund Activity: Q2 2014 in Review
12 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q2 2014, worth a combined $3.78M — down 26% from $5.08M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CRMD and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 5 added.
The largest buyer was Vanguard Group, adding an estimated $121K. The largest seller was Spark Investment Management, exiting entirely with an estimated $146K sold.
- 12 institutional investors held CorMedix (CRMD) as of Q2 2014, down from 14 in Q1 2014.
- Funds reported $3.78M of CorMedix stock for Q2 2014, down 26% quarter-over-quarter.
- 2 funds opened new CorMedix positions in Q2 2014 and 4 closed out, a net change of -2 holders.
- The largest CorMedix buyer in Q2 2014 was Vanguard Group, an estimated $121K added.
- The largest CorMedix seller in Q2 2014 was Spark Investment Management, an estimated $146K sold.
Based on aggregated 13F filings for Q2 2014.